The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 2.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 20%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (6 analysts) rates it none, with a mean price target of $29.
USA Compression Partners, LP
USAC · the NYSE · USD · Market cap $3.6B · 885 employees
USA Compression Partners, LP provides natural gas compression services in the United States.
FAIL · Does not pass the screenPrice as of 18 Nov 2026Daily close, not a live quote
Screened 2026-11-18 · the tape above runs as of 08:05 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price24.35 USD at the 18 Nov 2026 close
- Our value readOvervalued vs our fair value, as of 18 Nov 2026
- Our regime readMarkup, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans heavily to calls (put/call 0.62)
- Last reviewed18 Nov 2026 (2 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $21.51 to $24.74, base estimate $21.51 (screen dated 2026-11-18).
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.62, read 2026-11-15
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
USA Compression Partners, LP holds its Markup at $24.35. Consolidating, no directional conviction, held for 11 days.
| Phase | Markup |
| Quantitative state | Consolidating, no directional conviction, held for 11 days |
| Price at the screen | $24.35 |
| Valuation | 21.91 trailing · 14.91 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 0.27 |
Five Screens: USAC's Results
FAIL. Debt ratio
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | 96.75% | Below 33% | Fail |
| Interest-bearing cash | 0.00% | Below 33% | Pass |
| Receivables | 3.41% | Below 49% | Pass |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadWhy It Falls Short, in Plain English
USA Compression Partners, LP's business is in a permissible area, but its interest-bearing debt is about 97% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-19. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when USAC's ethical verdict changes
Today USAC does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Overvalued vs our fair value, as of 18 Nov 2026: it trades above our $21.51 fair value estimate, 42.70% revenue growth.
Model construction and limits: fair-value methodology.
Fair value range in USD, drawn from the 2026-11-18 screen. The gold marker is the market price at the same screen. The price runs 13.2% above the base estimate.
Third-party analyst targets: 5 covering, consensus Hold. The average target sits +19% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & ProjectionsWhere our models see it going: fair-value estimate $21.51, with a range of $21.51 to $24.74, dated to the 2026-11-18 screen.
How our estimate and third-party targets differ.
The Business, in Plain WordsCompression Pumps Ride A Volatile Energy Cycle
Picture a fleet of compressors humming only when drillers are flush with cash and gas volumes surge. USA Compression Partners keeps those machines running for producers across the US, yet the shares trade above our fair value with a negative margin of safety. Strong recent revenue growth and an eye-catching ROE do not change the fact that the current price leaves no room for error in a business tied to commodity swings.
The forward multiple sits at a seemingly modest level, but this is exactly the cyclical value trap we flag. Peak earnings and high returns on equity often coincide with the top of the cycle, making a low multiple a warning rather than a bargain. Analyst targets sit higher, yet the consensus remains a hold and our opportunity rating is none.
Risk sits in the energy price cycle itself. When drilling slows, utilisation and cash flow can drop sharply, and the unknown moat offers little protection. Ethical screen passes, but valuation and sector timing do not line up. Analysis, not advice.
| Forward P/E | 14.9xcheap for a company growing this fast |
| Trailing P/E | 21.9xa premium valuation |
| EPS, trailing | 1.13 |
| EPS, forward | 1.66 |
| Revenue growth | +42.7%growing very fast |
| Profit margin | 12.4%thin but positive margins |
| Return on equity | 175.1%an exceptional return on shareholder capital |
| FCF yield | 6.29% |
| Dividend yield | 7.31% |
| Debt to equity | 11.70heavy leverage: higher risk if revenue softens |
| Current ratio | 1.46adequate liquidity, worth monitoring |
| Beta | 0.27barely tracks the market's swings |
| Short interest, float | 0.02% |
| 52-week range | 22.65 - 30.55 |
| Market cap | $3.6B |
| Employees | 885 |
USAC-specific watchpoints · The things to watch: it carries a real debt load, which raises the stakes if revenue slips.
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
The framework has shifted from accumulation to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 20%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (6 analysts) rates it none, with a mean price target of $29.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 20%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (6 analysts) rates it none, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 20%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (6 analysts) rates it none, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 20%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (6 analysts) rates it none, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 20%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (6 analysts) rates it none, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 20%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (6 analysts) rates it none, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 2.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 20%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (6 analysts) rates it none, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 20%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (6 analysts) rates it none, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 20%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (6 analysts) rates it none, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- USA Compression Partners Q3 Earnings Call Highlights Yahoo Finance · 16d ago
- USA Compression Partners LP (USAC) (Q3 2026) Earnings Call Highlights: Record Revenue and ... Yahoo Finance · 16d ago
- USA Compression Partners, LP Q3 2026 Earnings Call Summary Yahoo Finance · 16d ago
- Compared to Estimates, USA Compression (USAC) Q3 Earnings: A Look at Key Metrics Yahoo Finance · 17d ago
- USA Compression: Q3 Earnings Snapshot Yahoo Finance · 17d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $27.43 | +1.5% | · | $1,015 | +1.5% |
| 2 months | $27.04 | +2.9% | $0.53 | $1,049 | +4.9% |
| 3 months | $26.73 | +4.1% | $0.53 | $1,061 | +6.1% |
| 6 months | $23.63 | +17.8% | $1.05 | $1,222 | +22.2% |
| 1 year | $23.27 | +19.6% | $2.10 | $1,286 | +28.6% |
| 2 years | $20.21 | +37.7% | $4.20 | $1,585 | +58.5% |
| 3 years | $15.45 | +80.1% | $6.30 | $2,209 | +120.9% |
| 5 years | $9.64 | +188.6% | $10.50 | $3,974 | +297.4% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever USAC does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.